BCAB a medical technology penny stock had a good beat on earnings. This means the cash burn was only 70% of what was expected. On the strength of that traders reached. The indicators suggest more upside including RSI lines crossing over the 50 level and the MACD lines bouncing up on the approach to the zero horizontal line. The supply and demand...
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It...
Holding a key level of support and consolidating nicely for a bounce.